Praveen Rastogi, MD
Sleep Medicine · Stockbridge, GANPI 1265406375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by GSK at 25.5% of the total.
Across 334 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Harmony Biosciences LLC$1K
- Jazz Pharmaceuticals Inc.$913
- Boehringer Ingelheim$638
- Axsome Therapeutics, Inc.$388
- AstraZeneca$340
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,84197%
- Education$1903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 96 | $1,796 |
| Harmony Biosciences LLC | 51 | $1,293 |
| Jazz Pharmaceuticals Inc. | 37 | $913 |
| Boehringer Ingelheim | 31 | $638 |
| Axsome Therapeutics, Inc. | 17 | $388 |
| AstraZeneca | 19 | $340 |
| Lilly USA, LLC | 6 | $119 |
| Eisai Inc. | 7 | $115 |
| Amgen | 5 | $115 |
| Inspire Medical Systems, Inc. | 3 | $114 |
| Actelion Pharmaceuticals US, Inc. | 6 | $97 |
| Sanofi | 4 | $94 |
| Bayer | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Resmed Corp | 5 | $72 |
| Grifols USA, LLC | 4 | $72 |
| United Therapeutics Corporation | 3 | $69 |
| Mallinckrodt Enterprises LLC | 3 | $65 |
| Mylan Specialty L.p. | 3 | $52 |
| Covis Pharma GmbH | 2 | $45 |
| Verona Pharma, Inc. | 2 | $45 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $43 |
| Kaleo, Inc. | 2 | $41 |
| Insmed, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $39 |
| Genentech USA, Inc. | 2 | $38 |
| Pfizer | 2 | $34 |
| Merck | 2 | $27 |
| Inari Medical, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Advanced Respiratory, Inc | 1 | $22 |
| Optinose US, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$247
- XYREM$121
- Wakix$112
How this compares
$7,031 in reported general payments places this provider in the 80th percentile of 50 sleep medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 11 | $236,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $143,871 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,990 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $17,033 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $13,468 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $11,891 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $9,346 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $7,759 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 244 | $6,130 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $2,330 |
| Armodafinil | 17 | $1,493 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,422 |
| Fluticasone Propionate | 82 | $1,025 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $991 |
| Azelastine Hcl | 22 | $842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,796 | $170,250231 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $340 | $29,88162 claims |
| Boehringer IngelheimStiolto Respimat | $638 | $13,46818 claims |
| Hikma Pharmaceuticals USAPhenobarbital | $16 | $20312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 sleep medicine providers in Georgia.
Other sleep medicine in Stockbridge
- Cosmo FowlerStockbridge$919
- Murad AssaadAtlanta$139K
- Nancy CollopAtlanta$28K
- Scott LeibowitzAtlanta$22K
- Anuj ChandraTrenton$20K
- Chantale BransonAtlanta$17K
- Melissa RhodesCartersville$14K
- James DalySavannah$12K
- Romy HoqueAtlanta$10K
- Naseer HumayunDalton$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.